The deal is valued at over $1.5 billion and will grant Sentivera global rights to develop, manufacture, and commercialize a preclinical drug targeting type 2 inflammatory diseases, excluding Greater China.
Artificial intelligence (AI) in drug discovery has attracted increasing interest over the past decade. It is now time for a critical review of progress in the field: where did we advance — and where are we yet to see impact — when it comes to what matters in drug discovery, which is to deliver safer…
Alkeus brought to late-stage testing a Stargardt disease therapy that former executive chairman and Vertex founder Josh Boger once called, “if it works, the most perfect drug I’ve ever seen.”
Expedition Therapeutics, which has raised nearly $300 million to date, is studying a drug it believes to have notable advantages over other COPD treatments either in development or on the market.
